CBR1 Polyklonale Antilichaam, APC-Cy5.5 Vervoeging

NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.

Carbonyl reductase [NADPH] 1; CBR1; 15-hydroxyprostaglandin dehydrogenase [NADP (+) ]; NADPH-dependent carbonyl reductase 1; Prostaglandin 9-ketoreductase; Prostaglandin-E (2) 9-reductase (EC:1.1.1.189) ; Short chain dehydrogenase/reductase family 21C member 1; CBR; CRN; SDR21C1

873

P16152

Cytoplasm

Mouse

201-277/277

CBR1

APC-Cy5.5

KLH conjugated synthetic peptide derived from human CBR1

WB, IF (IHC-P), IF (IHC-F), IF (ICC)

Purified by Protein A.

650nm/694nm

1µg/µl

WB (1:300-5000), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

873

Human, Rat